<p>藥明合聯 (02268.HK) +1.050 (+1.966%) 空頭頭寸 $61.54M; 比率 21.540% 宣佈公司決定利用內部資金最多達 1 億美元，委託專業受託人根據公司不時的股份計劃在公開市場以現行市場價格購買股份。</p>
<p>公司認為，當前股份的交易價格並未反映其內在價值或公司的實際商業前景，這為公司進行擬議的股份回購提供了良好機會。</p>
<p>藥明合聯今早開盤上漲 2.15%，報 HKD54.55，盤前交易 19,600 股，涉及 HKD1.07 百萬。</p>
<p>（香港股票報價延遲至少 15 分鐘。空頭數據截至 2026-05-18 16:25。）</p>

藥明合聯

<p>藥明合聯開盤上漲 2.15%，報 54.55 港元，成交 19,600 股。該公司宣佈計劃回購最多 1 億美元的股份，認為當前的交易價格並未反映其內在價值或商業前景</p>

<p>WUXI XDC (02268.HK) +1.050 (+1.966%)  Short selling $61.54M; Ratio 21.540%  announced that it resolved to utilize internal funds of up to US$100 million for the professional trustee appointed by the Company in respect of the share schemes of the Company from time to time to purchase the Shares in the open market at the prevailing market price.</p>
<div class="lb-trans"><p>藥明合聯 (02268.HK) +1.050 (+1.966%) 空頭頭寸 $61.54M; 比率 21.540% 宣佈公司決定利用內部資金最多達 1 億美元，委託專業受託人根據公司不時的股份計劃在公開市場以現行市場價格購買股份。</p>
</div><p>The Company believed that the current trading price of the Shares does not reflect their intrinsic value or the actual business prospects of the Company, which represents a good opportunity for the Company to conduct the Proposed Share Purchase.</p>
<div class="lb-trans"><p>公司認為，當前股份的交易價格並未反映其內在價值或公司的實際商業前景，這為公司進行擬議的股份回購提供了良好機會。</p>
</div><p>WUXI XDC opened 2.15% higher this morning at HKD54.55, with 19,600 shares traded in the pre-market session, involving HKD1.07 million.</p>
<div class="lb-trans"><p>藥明合聯今早開盤上漲 2.15%，報 HKD54.55，盤前交易 19,600 股，涉及 HKD1.07 百萬。</p>
</div><p>(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-18 16:25.)</p>
<div class="lb-trans"><p>（香港股票報價延遲至少 15 分鐘。空頭數據截至 2026-05-18 16:25。）</p>
</div>

藥明合聯開盤上漲 2.15%，計劃回購股份金額最高達 1 億美元